EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy

Young Joo Lee iD, Yoon Kyung Shin iD, Nae Ry Kim iD, Se Ik Kim iD, Yoo-Young Lee iD, Jeong-Yeol Park iD, Jae-Weon Kim iD, Hyun-Woong Cho iD, Jung-Yun Lee iD

Journal of Gynecologic Oncology · 2024

DOI: 10.3802/jgo.2024.35.e73 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Young Joo Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Bevacizumab, Mutation, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: We aimed to revalidate the chemotherapy response score (CRS) system as a prognostic factor for ovarian cancer patients with breast cancer gene (BRCA) mutations or those receiving frontline poly-ADP ribose polymerase (PARP) inhibitors or bevacizumab as maintenance therapy. METHODS: A retrospective analysis was performed using medical records of patients with high-grade serous carcinoma who received neoadjuvant chemotherapy followed by interval debulking surgery between January 2007 and December 2021 at 5 tertiary medical institutions in South Korea. At each hospital, pathologists independently assessed each slide of omental tissues obtained from surgery using the CRS system. Progression-free survival (PFS) and overall survival (OS) values were obtained using Kaplan-Meier analysis to evaluate the effect of BRCA mutation, maintenance therapy, and CRS on survival time. RESULTS: Of 466 patients, BRCA mutations were detected in 156 (33.5%) and 131 (28.1%) were treated with maintenance therapy; 98 (21.0%) and 42 (9.0%) were treated with PARP inhibitors or bevacizumab, respectively. Patients with CRS3 had significantly longer PFS than those with CRS1 or 2 (24.7 vs. 16.8 months, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsBevacizumabMutationPoly(ADP-ribose) Polymerase InhibitorsCystadenocarcinoma, SerousMaintenance ChemotherapyHumansFemaleRetrospective StudiesMiddle AgedAgedAdultProgression-Free SurvivalNeoadjuvant TherapyBRCA1 ProteinPrognosisCytoreduction Surgical ProceduresAntineoplastic Combined Chemotherapy ProtocolsBRCA2 ProteinNeoplasm GradingRepublic of KoreaGenes, BRCA1

Stichwörter der Autor:innen

BRCA1 ProteinBRCA2 ProteinBevacizumabNeoadjuvant ChemotherapyOvarian CancerPARP Inhibitors

Substanzen

BevacizumabPoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Asan Medical Center, Ulsan University Medical School, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea. jungyunlee@yuhs.ac.

ORCID-Profile: Young Joo Lee, Yoon Kyung Shin, Nae Ry Kim, Se Ik Kim, Yoo-Young Lee, Jeong-Yeol Park, Jae-Weon Kim, Hyun-Woong Cho, Jung-Yun Lee

Zitieren

APA

Lee, Y. J., Shin, Y. K., Kim, N. R., Kim, S. I., Lee, Y. Y., Park, J. Y., Kim, J. W., Cho, H. W., & Lee, J. Y. (2024). Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e73

Vancouver

Lee YJ, Shin YK, Kim NR, Kim SI, Lee YY, Park JY, et al. Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e73

BibTeX
@article{Lee2024,
  author = {Lee, Young Joo and Shin, Yoon Kyung and Kim, Nae Ry and Kim, Se Ik and Lee, Yoo-Young and Park, Jeong-Yeol and Kim, Jae-Weon and Cho, Hyun-Woong and Lee, Jung-Yun},
  title = {Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  doi = {10.3802/jgo.2024.35.e73}
}
Kostenlos starten →